From the Journals

Occult HCV infection is correlated to unfavorable genotypes in hemophilia patients


 

FROM INFECTION, GENETICS AND EVOLUTION

The presence of occult hepatitis C virus infection is determined by finding HCV RNA in the liver and peripheral blood mononuclear cells, with no HCV RNA in the serum. Researchers have shown that the presence of occult HCV infection (OCI) was correlated with unfavorable polymorphisms near interferon lambda-3/4 (IFNL3/4), which has been associated with spontaneous HCV clearance.

This study was conducted to assess the frequency of OCI in 450 hemophilia patients in Iran with negative HCV markers, and to evaluate the association of three IFNL3 single nucleotide polymorphisms (rs8099917, rs12979860, and rs12980275) and the IFNL4 ss469415590 SNP with OCI positivity.

The estimated OCI rate was 10.2%. Among the 46 OCI patients, 56.5%, 23.9%, and 19.6% were infected with HCV-1b, HCV-1a, and HCV-3a, respectively. The researchers found that, compared with patients without OCI, unfavorable IFNL3 rs12979860, IFNL3 rs8099917, IFNL3 rs12980275, and IFNL4 ss469415590 genotypes were more frequently found in OCI patients. Multivariate analysis showed that ALT, cholesterol, triglyceride, as well as the aforementioned unfavorable interferon SNP geneotypes were associated with OCI positivity.

“10.2% of anti-HCV seronegative Iranian patients with hemophilia had OCI in our study; therefore, risk of this infection should be taken into consideration. We also showed that patients with unfavorable IFNL3 SNPs and IFNL4 ss469415590 genotypes were exposed to a higher risk of OCI, compared to hemophilia patients with other genotypes,” the researchers concluded.

The authors reported that they had no disclosures.

SOURCE: Nafari AH et al. Infect Genet Evol. 2019 Dec 13. doi: 10.1016/j.meegid.2019.104144.

Recommended Reading

Updated international consensus recommendations on management of acute upper GI bleeding
MDedge Hematology and Oncology
ISTH releases draft guideline for TTP diagnosis, treatment
MDedge Hematology and Oncology
Fibrinogen concentrate effective, safe for postop bleeding
MDedge Hematology and Oncology
Emicizumab effective in children with hemophilia A and inhibitors
MDedge Hematology and Oncology
Fresh RBCs offer no benefit over older cells in pediatric ICU
MDedge Hematology and Oncology
Best practice alerts really can work
MDedge Hematology and Oncology
Think twice: Choosing Wisely recommendations on testing to avoid in pediatric hematology
MDedge Hematology and Oncology
Phase 2 studies show potential of FcRn blockade in primary ITP
MDedge Hematology and Oncology
Age, sex, and other factors linked to risk of intracranial hemorrhage in ITP
MDedge Hematology and Oncology
Turoctocog alfa prevented, treated bleeds in previously untreated pediatric patients with severe hemophilia A
MDedge Hematology and Oncology